Results of 2 recent randomized trials showing lack of correlation between regimens that provide better depth of response and survival
| Reference . | Regimen . | No. of patients . | CR, % . | CR plus VGPR, % . | Median PFS, months . | P for PFS . | OS . | P for OS . |
|---|---|---|---|---|---|---|---|---|
| Harousseau et al40 (2010) | VAD | 242 | 9 | 37 | 30 | .06 | 3-yr, 77% | .5 |
| VD | 240 | 16 | 54 | 36 | 3-yr, 81% | |||
| Ludwig et al41 (2009) | MP | 143 | 2 | 13 | 21 | .1 | Median, 49 mo | .02* |
| TD | 145 | 2 | 26 | 17 | Median, 42 mo |
| Reference . | Regimen . | No. of patients . | CR, % . | CR plus VGPR, % . | Median PFS, months . | P for PFS . | OS . | P for OS . |
|---|---|---|---|---|---|---|---|---|
| Harousseau et al40 (2010) | VAD | 242 | 9 | 37 | 30 | .06 | 3-yr, 77% | .5 |
| VD | 240 | 16 | 54 | 36 | 3-yr, 81% | |||
| Ludwig et al41 (2009) | MP | 143 | 2 | 13 | 21 | .1 | Median, 49 mo | .02* |
| TD | 145 | 2 | 26 | 17 | Median, 42 mo |
VGPR indicates very good partial response; VD, bortezomib plus dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; MP, melphalan plus prednisone; and TD, thalidomide plus dexamethasone.
In favor of MP over TD.